Advertisement

Topics

Novartis and BMS partner up to explore Mekinist/Opdivo combinations

06:36 EDT 6 Jun 2017 | Pharmafile

Novartis and Bristol-Myers Squibb have announced they are to enter a clinical research partnership to investigate and assess the effectiveness of utilising Mekinist (trametinib) and Opdivo (nivolumab) in combination as a treatment for metastatic colorectal cancer in patients with microsatellite stable tumours which are proficient in mismatch repair (MSS mCRC pMMR).

read more

Original Article: Novartis and BMS partner up to explore Mekinist/Opdivo combinations

NEXT ARTICLE

More From BioPortfolio on "Novartis and BMS partner up to explore Mekinist/Opdivo combinations"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...